Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,127.20
(
0.47%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
98.81
(
-1.83%
)
Bitcoin
74,075.35
(
0.18%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 76401

Saturday, 05/09/2009 11:31:11 AM

Saturday, May 09, 2009 11:31:11 AM

Post# of 257253
RDEA cuts workforce by 47% and has apparently dropped RDEA806 in HIV:

http://finance.yahoo.com/news/Ardea-Biosciences-Reports-bw-15180529.html

Despite a detailed pipeline update in this PR, there is no mention of the RDEA806 program in HIV, which leads me believe that the program is effectively dead. I presume that RDEA shopped the program to various partners and found no interest. (RDEA had previously stated that it would not advance the program into phase-2b without a partner.)

The RDEA806 program in gout remains fully active, and the company has evidently settled on gout and cancer as its new foci.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now